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Abstract 
Biologically treated wastewater spiked with a mixture of 56 active pharmaceutical 
ingredients (APIs) was treated with 0-20 mg/L chlorine dioxide (ClO2) solution in 
laboratory-scale experiments. Wastewater effluents were collected from two 
wastewater treatment plants in Sweden, one with extended nitrogen removal (low 
COD) and one without (high COD). About one third of the tested APIs resisted 
degradation even at the highest ClO2 dose (20 mg/L), while others were reduced by 
more than 90% at the lowest ClO2 level (0.5 mg/L). In the low COD effluent, more 
than half of the APIs were oxidized at 5 mg/L ClO2, while in high COD effluent a 
significant increase in API oxidation was observed after treatment with 8 mg/L ClO2. 
This study illustrates the successful degradation of several APIs during treatment of 
wastewater effluents with chlorine dioxide. 
 
Keywords: Pharmaceuticals; Chlorine dioxide; Wastewater effluent 
 
1. Introduction  
One of the pressing problems in wastewater treatment plants (WWTPs) is the inability 
of conventional methods to completely remove active pharmaceutical ingredients 
(APIs) due to their high resistance to biodegradation and/or limited biological activity, 
especially in cold climates such as that in Sweden [1,2]. The extensive usage and 
hence release of traces of many pharmaceuticals in wastewater effluents may lead to 
surface and groundwater contamination compromising the aquatic ecosystem and the 
environment [3,4].  
Where biological treatment is not sufficient, improvement in WWTPs can be 
achieved by an additional chemical oxidation step to remove potential pollutants that 
cannot be degraded biologically [5,6,7,8]. Among the chemical oxidants applied in 
water treatment reported in the literature, chlorine dioxide is one that merits further 
investigation regarding its potential to remove APIs in wastewater. As in the case of 
ozonation, the application of chlorine dioxide to treat drinking water, surface water 
and wastewater effluents has shown promising results for the removal of 
pharmaceuticals. The non-steroidal anti-inflammatory drug diclofenac, reported as 
one of the most frequently detected compounds in water at concentrations up to the 
g/L level [9], is among the pharmaceuticals completely degraded during drinking 
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and surface water treatment at the lowest ClO2 dose applied [10]. In wastewater 
effluents, steroid estrogens and industrial estrogenic chemicals, as well as personal 
care products, were removed by low doses of ClO2 between 1.25 and 3.75 mg/L, and 
the removal of estrogenic potency was observed at the same time [11]. The removal of 
several antibiotics found in water has also demonstrated the ability of ClO2 as an 
oxidant [12,13].   
When ClO2 was used for selective oxidation of organic micropollutants in other 
investigations on biologically treated wastewater, it was found that smaller doses, e.g. 
up to 4 mg/L (depending on the concentrations tested and the matrix) were consumed 
in less than a minute through reactions with the soluble components in the water, 
while still completely removing many of the reactive micropollutants. This fast 
consumption of the oxidant in wastewater has been observed in previous studies by 
Andersen [11], Hey et al. [14], Lee and von Gunten [6] and Andersen et al. [15]. 
Based on ClO2 reactivity in wastewater effluents, it has been suggested that ClO2 
could be used as an alternative to ozone for the removal of micropollutants. It is easy 
to introduce a ClO2 dosing step in a WWTP since ClO2 is produced as a solution in 
water by mixing aqueous solutions of the reactants in a simple reactor; furthermore, 
the ClO2 stock solution is semi-storable. This is much simpler than treatment with 
ozone, which requires on-site delivery of dry oxygen and considerable electric power 
to run an expensive and complicated ozone generator which produces an ozone gas 
mixture with less than 20% ozone yield. Following the generation of ozone, the gas 
must be transferred to the water using a gas contact reactor, usually with 5-20 min 
hydraulic retention time [5,7,16].  
When ClO2 is used for oxidation of water with low NOM (natural organic 
matter), most of the ClO2 is reduced to chlorite by reactions with the organic matter. 
Chlorate is also formed as a by-product, but at a much lower concentration than 
chlorite [17, 18,19]. According to Korn [18] and Lee [19], the formation of chlorite 
and chlorate accounts for about 70% and 10%, respectively, of the chlorine dioxide 
applied. In drinking water with low NOM, chlorite reacts slowly with organic matter 
and is reduced to chloride, while in wastewater, significantly more NOM is available 
to reduce the chlorite. Toxicity derived from chlorite residuals after treatment may be 
problematic depending on the concentration and degradation rate [20]. ClO2 differs 
from chlorine in that it produces very little chloro-organic by-products [11,15,21].  
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The formation of undesirable by-products can be controlled by minimizing the dose of 
ClO2 and applying post-treatment using, for example, ferrous iron (Fe2+) or sulfite 
(SO32-), which reduces ClO2 and chlorite residuals to chloride [22,23]. The removal of 
ClO2 and chlorite residuals allows higher levels of ClO2 to be used for treatment 
providing effective micropollutant removal. 
In this study, the removal of 56 different APIs in biologically treated wastewater 
was investigated in both low- and high-COD effluents using different doses of 
chlorine dioxide. The APIs were chosen to represent different classes of 
pharmaceuticals commonly sold and used in Sweden, which will most likely end up in 
WWTP effluents due to their low sorption to sludge [24]. The effectiveness of the 
treatment was evaluated by monitoring the oxidant consumption and the amount of 
APIs oxidized. Oxidation by-products were not evaluated in this study as the aim was 
to determine the most suitable oxidant dose and identify which APIs can be removed. 
Once the relevant dose has been determined, attention can be turned towards 
investigating the ClO2 by-products.   
 
2. Materials and methods 
 2.1. Chemicals 
 All pharmaceutical reference standards were purchased as solids of analytical grade 
(>98%) from different suppliers. All APIs investigated are listed in Supplementary 
Information Table S1. Methanol and acetonitrile were of LC/MS grade (Merck, 
Darmstadt, Germany). Ultrapure water was prepared from deionized water using a 
Milli-Q Gradient system (Millipore, Billerica, MA), equipped with a UV radiation 
source. A stock solution of APIs was prepared in methanol at concentration of about 
100 mg/L. Solutions for spiking and analysis were prepared by precise dilution of the 
stock solution. Chlorine dioxide was synthesized by adding equal volumes (25 mL 
each) of 9% HCl (Merck, Darmstadt, Germany) and 7.5% NaClO2 (Sigma Aldrich, 
Steinheim, Germany) to 400 mL deionized water. The solution was allowed to react in 
the dark for at least 10 hours and then diluted to 1000 mL with water. This resulted in 
an approximately 1 g/L ClO2 stock solution. 
2.2. Analytical methods 
The concentration of residual ClO2 was quantified by reaction with DPD (N,N-
diethyl-p-phenylenediamine) using an Allcon spectrophotometer (Alldos GmbH, 
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Germany) with a built-in calibration line for ClO2. The analysis of ClO2 with DPD 
was performed according to the manufacturer’s instructions.  
For the analysis of the APIs, samples of 100 mL treated effluent were filtered 
using a 0.45 m membrane filter (Millipore, Ireland) then acidified to pH 3 using 
sulfuric acid. Five ng of 13C- and 2H-labelled APIs was added as internal standards, to 
each sample (see Supplementary Table 1 for the complete list) before solid-phase 
extraction using Oasis HLB columns (200 mg, Waters). LC/MS/MS analysis of the 
extracts was carried out using a triple-stage quadrupole mass spectrometer (MS/MS 
TSQ Quantum Ultra EMR) coupled to an Accela LC pump (both from Thermo Fisher 
Scientific, San Jose, CA, USA) and a PAL HTC autosampler (CTC Analytics AG, 
Zwingen, Switzerland) with a Hypersil GOLD aQTM column (50 mm x 2.1 mm ID x 5 
µm particles). Both heated electrospray and atmospheric pressure photoionization 
were used in positive and negative ion modes for the ionization of target compounds. 
Two MS/MS transitions were measured for each API. Samples were quantified using 
isotope dilution or internal standard methods. Six points calibration curve 
corresponding to concentration ranges 10 to 2500 ng/L were measured before, in the 
middle and at the end of sample analysis sequence to monitor response factor 
stability. Recoveries and the relative standard deviation of triplicate analyses of 
effluent from the Sjölunda WWTP spiked at 1µg/L are given in Supplementary 
Information Table S2. Maximum difference between results at quantification and 
qualification mass transition was set to 30% as criterion for positive identification of 
the analyte. The same method is used by Hörsing et al. [24] and Grabic et al. 
(unpublished results) [25].  
2.3. Experimental setup 
2.3.1. Wastewater effluents 
Wastewater effluents were collected after secondary treatment from two WWTPs in 
southern Sweden. Effluent 1 was collected from Källby WWTP after the activated 
sludge system which is operated with extended nitrogen removal.  
Effluent 2 was obtained from Sjölunda WWTP after a high loaded activated 
sludge process before nitrogen removal. This wastewater is typical of that in many 
Swedish WWTPs which are operated without nitrogen removal due to their location 
in the northern part of the country where the climate is colder. Sjölunda also employs 
full nitrogen removal but using a biofilm system after a highly loaded activated sludge 
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plant. Nitrification is achieved in trickling filters and denitrification in moving bed 
biofilm reactors with the addition of external carbon.  
Table 1 gives the characteristics of the effluents. The effluents were analyzed 
using standard Swedish methods for total suspended solids (SS-EN 872:2005), total P 
(SS-EN ISO 6878:2005) and total N (SS-EN ISO 11905-1), while COD was 
determined with the Dr. Lange LCK 114 kit. The effluents were classified as low 
COD (Effluent 1) or high COD effluent (Effluent 2) based on their COD levels. 
 
Table 1 
Effluent characteristics 
 
2.3.2. Oxidation experiments 
Effluent samples of 150 mL each were prepared in Schott Duran® bottles and spiked 
with mixed APIs to a final concentration of approx. 1 g/L. ClO2 was added to 
duplicate samples at concentrations ranging from 0-20 mg/L. All samples were stored 
in the dark and allowed to react overnight (approx. 18 h) at room temperature, after 
which the pH and oxidant concentration in the samples were measured. Residual 
oxidants were removed by the addition of 50 mg/L sodium sulfite.  
 
3. Results and discussion 
Table 2 lists the APIs investigated, including information on the class of drug, 
arranged according to the ease with which they were oxidized by ClO2 (based on 
Effluent 1). 
No further pH adjustments were made during the entire experiment. The pH of 
the samples did not change significantly after treatment, even with the highest oxidant 
dose of 20 mg/L, where the sample remained slightly acidic (~pH 6.2-6.5).  This 
slight decrease in pH is expected since the stock solutions of ClO2 contain some 
residual HCl from the synthesis.  
 
 
 
 pH COD 
(mg/L) 
TSS 
(mg/L) 
Total P 
(mg/L) 
Total N 
(mg/L) 
Effluent 1 (Källby) 6.8 35 5 0.26 7.5 
Effluent 2 (Sjölunda) 7.2 55 8 0.28 8.0 
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Table 2 
Name and chemical structure of the APIs investigated (www.fass.se). The therapeutic class, 
and in the case of the easily and moderately oxidizable APIs the reactive functional group are 
given in brackets.  
Easily oxidized (0.5-1.25 mg/l ClO2) 
Buprenorphine 
(narcotic analgesic; 
phenol)          
  
 
Ciprofloxacin 
(antibiotic; 
tertiary amine) 
 
 
Clindamycine 
(antibiotics; tertiary 
amine) 
 
 
Diclofenac 
(antiphlogistic; 
aniline)  
 
Dipyridamole 
(antiplatelet; 
tertiary 
amine) 
 
 
Estriol 
(hormone; 
phenol) 
 
 
Estrone 
(hormone; 
phenol) 
Ethinyl 
estradiol 
(hormone; 
phenol) 
 
Naloxone 
(narcotic antagonist; 
phenol) 
 
Promethazine 
(antihistamine; 
tertiary amine) 
Repaglinide 
(antidiabetic; 
tertiary amine) 
Moderately oxidized (2.5-5 mg/L ClO2) 
Alfuzosin 
(α-blocker; tertiary amine) 
Biperiden 
(antiparkinson; 
tertiary amine) 
Cilazapril 
(ACE 
inhibitor; 
tertiary amine) 
Codeine 
(narcotic analgesic; 
tertiary amine) 
Dicyloverin 
(anticholinergic; tertiary amine) 
 
 
Diltiazem 
(calcium 
antagonist; tertiary 
amine) 
 
Diphenhydramine 
(anxiolytic; 
tertiary amine) 
 
 
Fexofenadine 
(antihistamine; tertiary 
amine) 
 
 
 
Hydroxyzine 
(antihistamine; tertiary amine) 
        
 
 
Mianserin 
(antidepressant; 
tertiary amine) 
 
Mirtazapine 
(antidepressant; 
tertiary amine) 
 
 
Orphenadrine 
(anticholinergic; 
tertiary amine) 
 
 
Paroxetine 
(antidepressant; 
secondary amine, 
cyclic) 
 
Risperidone 
(antipsychotic; tertiary amine) 
 
 
 
Sotalol 
(β-locker; 
sulfonamide) 
 
Sulfamethoxazole 
(antibiotic; aniline) 
 
 
Tramadol 
(narcotic analgesic; 
tertiary amine) 
 
 
 
Trihexyphenidyl 
(antiparkinson; 
tertiary amine) 
 
Venlafaxine 
(antidepressant; 
tertiary amine) 
 
 
Zolpidem 
(sedative hypnotic; tertiary 
amine) 
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Table 2. Continued. 
Poorly oxidized (8-20 mg/L ClO2) 
Amitriptyline 
(antidepressant) 
 
 
Atracurium 
(neuromuscular blocker) 
 
Citalopram 
(antidepressant) 
 
 
Cyproheptadine 
(antihistamine) 
 
 
Eprosartan 
(AR  
blocker) 
 
 
 
 
Memantine 
(antidementia) 
 
Pizotifen 
(serotonin 
antagonist) 
 
 
Trimethoprim 
(antibiotic) 
 
 
 
  Non-oxidizable   
Alprazolam 
(anxiolytic) 
 
 
Beclomethasone 
(synthetic steroid) 
 
 
Bezafibrate 
(lipid regulator) 
 
 
 
Bisoprolol 
(β-blocker) 
 
 
 
Budesonide 
(synthetic steroid) 
 
 
 
Bupropion 
(antidepressant) 
 
 
 
Carbamazepine 
(antiepileptic) 
 
 
Clonazepam 
(antiparkinson) 
 
Desloratidine 
(antihistamine) 
 
 
 
Finasteride 
(antiandrogen) 
 
 
 
 
Flutamide 
(antiandrogen) 
 
 
Fluconazole 
(antifungal) 
Fluoxetine 
(antidepressant) 
 
 
Irbesartan 
(AR blocker) 
 
 
 
 
Maprotiline 
(antidepressant) 
 
 
 
Metoprolol 
(β-blocker) 
 
Telmisartan 
(AR blocker) 
 
 
 
 
Figure 1 shows the residual concentration of ClO2 in the two effluents spiked 
with APIs as a function of the initial ClO2 dose. It can be seen that the high COD 
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effluent consumed more oxidant than the low COD effluent, especially when the dose 
was 8 mg/L ClO2 and above.  
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Figure 1. Residual concentration of ClO2 in the 2 effluents after treatment with different 
doses of the oxidant. 
 
Table 3 gives the number of APIs that can be effectively oxidized (i.e. by more 
than 90%) at each ClO2 dose in both effluents. It can be seen that a dose of 8 mg/L 
ClO2 to Effluent 1 was able to oxidize 38 of 56 APIs, and that only 1 more API was 
oxidized when the dose was increased to 20 mg/L. In Effluent 2, 33 APIs were 
oxidized with a dose of 8 mg/L ClO2, and increasing the ClO2 dose to 20 mg/L 
oxidized further 4 APIs. The remaining APIs (about one third) could not be degraded 
effectively (at least 90%) with a dose of 20 mg/L ClO2. 
Only few APIs were oxidized by more than 90% at the lowest dose of ClO2 (0.5 
mg/L), while high oxidative degradation was observed with higher doses (8-20 mg/L). 
The degree to which each API was oxidized at different ClO2 doses is shown in Figure 
2A and 2B for Effluents 1 and 2, respectively. The vertical lines divide the APIs into 
easily, moderately, poorly (based on the ClO2 dose required to achieve 90-100% 
degradation) and non-oxidizable APIs (less than 90% degradation with 20 mg/L 
ClO2).  
As shown for Effluent 1 (Figure 2A and Table 2), 11 of the APIs from 8 different 
therapeutic classes could be oxidized by more than 90% with 0.5-1.25 mg/L ClO2. 
These include all 3 hormones, 2 antibiotics, 1 antihistamine, and 1 narcotic analgesic, 
Hey et al. 2012                            Accepted for publication in Chemical Engineering Journal  
10 
 
as well as the antiplatelet, antidiabetic, antiphlogistic and narcotic antagonist 
compounds. The common reactive and electron-rich functional groups in these APIs 
are aniline in diclofenac, phenol in hormones, buprenorphine, and naloxone, and 
tertiary amines in promethazine, clindamycine, dipyridamole, repaglinide and 
ciprofloxacin. The high reactivity of ClO2 with aniline, phenolic and tertiary amine 
functional groups has been reported in a number of studies [6,10,26]. The reactivity of 
ClO2 with the piperazine ring of the antibiotic ciprofloxacin has also been reported by 
Wang et al. [13].  Similarly, Navalon et al. [12] also showed high reactivity of 
ciprofloxacin with ClO2 in both surface water and wastewater effluent. 
 
Table 3 
The number of APIs tested (of a total of 56) that could be effectively oxidized (at least 90%) 
at each ClO2 dose  
 
  No. of APIs oxidized by > 90% 
ClO2 dose, mg/l (Effluent 1) (Effluent 2) 
0.5 4 0 
1.25 11 4 
2.5 15 8 
3.75 24 12 
5 31 18 
8 38 33 
10 38 36 
20 39 37 
 
APIs requiring doses of 2.5-5 mg/L ClO2 for oxidation are considered to be 
moderately oxidizable (Table 2). Most of the APIs from 13 of the different therapeutic 
classes belong to this category including 4 antidepressants, 2 antihistamines, 2 
antiparkinson drugs, 2 narcotic analgesics, 2 anticholinergics, 1 antibiotic, 1 beta 
blocker, 1 sedative-hypnotic, 1 anxiolytic, and the representative compound from 
different classes, namely angiotensin converting enzyme (ACE) inhibitor, alpha 
blocker, antipsychotic and calcium antagonist. The most common functional group in 
this category of moderately oxidizable APIs is the tertiary amino group, which is also 
found in the structures of easily oxidizable APIs. However, despite belonging to the 
same therapeutic class, the behavior of the APIs differed significantly, depending 
largely on the reactivity of electron-rich functional groups. The removal of 
pharmaceuticals at fairly low oxidant doses (1.25-3.75 mg/L ClO2) has also been 
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observed in previous studies on surface and drinking water [10] and in wastewater 
effluents [6,11].  
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Figure 2. Fraction of APIs oxidized in Effluent 1 (A) and Effluent 2 (B) at different ClO2 
doses. The vertical lines divide the APIs into groups according to their ease of oxidation. 
 
The resistance of poorly and non-oxidizable APIs to oxidation by ClO2 could be 
attributed to the presence of the electron-withdrawing functional groups such as the 
chloro (in clonazepam, bupropion, desloratidine, alprazolam, bezafibrate, and 
beclomethasone), fluoro (in citalopram, flutamide, fluoxetin, fluconazole), nitro (in 
flutamide and clonazepam), olefin or C=C double bonds (in eprosartan and 
amitriptyline), amide carbonyl (in bezafibrate and finasteride) and keto group (in 
bupropion, beclomethasone and budesonide) [7,26,27,28,29]. The secondary amine-
containing beta blockers, metoprolol and bisoprolol are also considered less 
susceptible to ClO2 oxidation. Lee and von Gunten [6] reported the poor 
transformation of the beta blocker atenolol which has a secondary amine functional 
group. However, the oxidizability of the beta blocker sotalol can be explained by the 
presence of the ClO2 reactive sulfonamide functional group in its structure. The same 
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degree of API oxidation can be achieved in the high COD effluent (2) as in the low 
COD effluent (1), but higher ClO2 doses are required. This is due to consumption of 
the ClO2 competitively with the APIs by other organic components in the wastewater 
[6]. In addition, the presence of inorganic components in the wastewater also 
consumes some of the oxidant and this could affect the removal of the target 
micropollutants [6]. 
The results of this study showed that about 20 APIs cannot be oxidized 
effectively, even at the highest dose investigated (20 mg/L ClO2), suggesting low 
reactivity between these APIs and ClO2. In Effluent 1, 13 of these APIs (alprazolam, 
finasteride, fluoxetine, beclomethasone, desloratadine, maprotiline, fluconazole, 
bezafibrate, flutamide, telmisartan, budesonide, bisoprolol, and clonazepam) were 
oxidized by 50-80%, while the remaining 4 APIs metoprolol, irbesartan, bupropion, 
and carbamazepine were degraded less (20-40%). On the other hand, in Effluent 2, 
most of these APIs were oxidized by less than 50%, while 3 APIs (the synthetic 
steroids beclomethasone and budesonide, and the antidepressant bupropion) did not 
show any degradation at all. Bezafibrate and carbamazepine have been shown in 
previous investigations to be recalcitrant to ClO2 oxidation during water and 
wastewater treatment [10,6,28]. As mentioned above, the presence of electron-
withdrawing functional groups results in low reactivity of some APIs to ClO2 
oxidation, and thus a much higher dose of ClO2 would be needed for oxidation. 
APIs such as diclofenac, sulfamethoxazole and estrogens have been found to be 
oxidized by more than 90% during ozonation of municipal wastewater effluents at O3 
doses of ≥ 2 mg/L, while a much higher O3 dose was required for the effective 
removal of bezafibrate [30].  Ternes et al. [7] also found significant removal (> 90%) 
of sulfamethoxazole, diclofenac, carbamazepine, and sotalol during treatment of 
municipal sewage effluent with 5 mg/L O3, while a higher O3 dose of 10-15 mg/L was 
required to effectively remove the beta blocker metoprolol, which also exhibits low 
reactivity to ClO2. In the present study, ClO2 was able to oxidize several APIs 
effectively at doses comparable to those of ozone. The reactivity of carbamazepine 
was very different since it could be removed by low ozone doses, while it is almost 
completely resistant to ClO2. 
The oxidation of APIs by ClO2 is comparable to oxidation by molecular ozone as 
both are selective oxidants and are capable of transforming organic micropollutants 
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based on the reactivity of the structure and the characteristics of the water matrix. 
These chemical oxidants react with electron-rich functional groups such as phenolic 
and amino groups, which can be found in the structures of most of the APIs 
investigated [6,10,31,32,33]. However, the reaction between ClO2 and some APIs was 
much slower than ozonation, even with the same reactive functional group. Therefore, 
the usefulness of ClO2 end-of-pipe treatment of WWTP effluents will depend on 
whether the micropollutants deemed to be critical for the receiving water are sensitive 
to ClO2. Running costs must also be considered since ClO2 is slightly more expensive 
to produce than ozone, while it is far simpler and less expensive to build both the 
generator and reaction chamber for ClO2 treatment. The treatment perspective then is 
mainly to use ClO2-treatment for small scale WWTP (< 2,000 person equivalent) 
effluents or where treatment is required only for a limited time. 
Two of the APIs investigated here may be of considerable concern regarding the 
discharge of wastewater effluents into surface water. Both ethinyl estradiol, a 
pharmaceutical with a high endocrine-disrupting ability [34], and diclofenac, 
identified as a contaminant that causes direct toxic effects in the environment [35,36], 
were found to be very sensitive to ClO2 oxidation. However, if other less reactive 
APIs, e.g. bezafibrate or carbamazepine, were found to be of concern regarding 
aquatic life in the receiving water body of the WWTP effluent, ClO2 treatment would 
not be a suitable treatment option.   
 
4. Conclusions 
The results of this study show that ClO2 can be used to treat wastewater effluents to 
oxidize various APIs belonging to different therapeutic classes. However, there was 
considerable variation in the reactivity of the investigated APIs to ClO2. The degree of 
oxidation was found to be dependent on the type of wastewater; API removal is better 
from the low COD wastewater from the plant with extended nitrogen removal, than 
the one without (high COD wastewater), at the same oxidant dose. In addition, the 
reactivity of the APIs depends on the reactive functional group present. APIs with 
electron-withdrawing functional groups appear to be more resistant to ClO2 oxidation. 
ClO2 oxidation by-products and toxicity must be investigated before this method 
can be considered for application in wastewater treatment. The use of ClO2 oxidation 
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for the removal of pharmaceuticals may be beneficial in small wastewater treatment 
plants where ozonation could be too expensive and complicated.  
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Table S1 
List of suppliers for APIs and the corresponding internal standards used for quantification. 
APIs Supplier Internal standards Supplier 
Alfuzosin Sigma-Aldrich (Steinheim, Germany) 13C2H3 - Tramadol Cambridge Isotope Laboratories (Andover, MA, 
USA) 
Alprazolam Sigma-Aldrich (Steinheim, Germany) 13C2H3 - Tramadol Cambridge Isotope Laboratories (Andover, MA, 
USA) 
Amitryptiline Sigma-Aldrich (Steinheim, Germany) 2H6 - Amitriptyline Cambridge Isotope Laboratories (Andover, MA, 
USA) 
Atracurium Sigma-Aldrich (Steinheim, Germany) 13C2H3 - Tramadol Cambridge Isotope Laboratories (Andover, MA, 
USA) 
Beclomethasone Sigma-Aldrich (Steinheim, Germany) 2H5 - Oxazepam Sigma-Aldrich (Steinheim, Germany) 
Bezafibrate Sigma-Aldrich (Steinheim, Germany) 2H5 - Oxazepam Sigma-Aldrich (Steinheim, Germany) 
Biperiden Sigma-Aldrich (Steinheim, Germany) 2H6 - Amitriptyline Cambridge Isotope Laboratories (Andover, MA, 
USA) 
Bisoprolol Sigma-Aldrich (Steinheim, Germany) 13C2H3 - Tramadol Cambridge Isotope Laboratories (Andover, MA, 
USA) 
Budesonide Sigma-Aldrich (Steinheim, Germany) 2H5 - Fluoxetine Cambridge Isotope Laboratories (Andover, MA, 
USA) 
Buprenorphine Sigma-Aldrich (Steinheim, Germany) 13C2H3 - Tramadol Cambridge Isotope Laboratories (Andover, MA, 
USA) 
Bupropion Sigma-Aldrich (Steinheim, Germany) 13C2H3 - Tramadol Cambridge Isotope Laboratories (Andover, MA, 
USA) 
Carbamazepine Sigma-Aldrich (Steinheim, Germany) 2H10 - Carbamazepine Cambridge Isotope Laboratories (Andover, MA, 
USA) 
Cilazapril LGC Standards (Middlesex, UK) 13C2H3 - Tramadol Cambridge Isotope Laboratories (Andover, MA, 
USA) 
Ciprofloxacin Sigma-Aldrich (Steinheim, Germany) 13C315N - Ciprofloxacin Cambridge Isotope Laboratories (Andover, MA, 
USA) 
Citalopram Sigma-Aldrich (Steinheim, Germany) 13C2H3 - Tramadol Cambridge Isotope Laboratories (Andover, MA, 
USA) 
Clindamycine Sigma-Aldrich (Steinheim, Germany) 13C2H3 - Tramadol Cambridge Isotope Laboratories (Andover, MA, 
USA) 
Clonazepam Sigma-Aldrich (Steinheim, Germany) 13C2H3 - Tramadol Cambridge Isotope Laboratories (Andover, MA, 
USA) 
Codeine Sigma-Aldrich (Steinheim, Germany) 13C2H3 - Tramadol Cambridge Isotope Laboratories (Andover, MA, 
USA) 
Cyproheptadine Sigma-Aldrich (Steinheim, Germany) 13C2H3 - Tramadol Cambridge Isotope Laboratories (Andover, MA, 
USA) 
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Desloratidine Sigma-Aldrich (Steinheim, Germany) 2H4 - Risperidone Sigma-Aldrich (Steinheim, Germany) 
Diclofenac Sigma-Aldrich (Steinheim, Germany) 13C2H3 - Tramadol Cambridge Isotope Laboratories (Andover, MA, 
USA) 
Dicycloverin LGC Standards (Middlesex, UK) 2H5 - Oxazepam Sigma-Aldrich (Steinheim, Germany) 
Diltiazem Sigma-Aldrich (Steinheim, Germany) 13C2H3 - Tramadol Cambridge Isotope Laboratories (Andover, MA, 
USA) 
Diphenhydramine Sigma-Aldrich (Steinheim, Germany) 13C2H3 - Tramadol Cambridge Isotope Laboratories (Andover, MA, 
USA) 
Dipyridamole Sigma-Aldrich (Steinheim, Germany) 13C2H3 - Tramadol Cambridge Isotope Laboratories (Andover, MA, 
USA) 
Eprosartan CHEMOS GmbH (Regenstauf, Germany) 2H10 - Carbamazepine Cambridge Isotope Laboratories (Andover, MA, 
USA) 
Estriol Sigma-Aldrich (Steinheim, Germany) 13C2 - Ethinyl estradiol Cambridge Isotope Laboratories (Andover, MA, 
USA) 
Estrone Sigma-Aldrich (Steinheim, Germany) 13C2 - Ethinyl estradiol Cambridge Isotope Laboratories (Andover, MA, 
USA) 
Ethinyl estradiol Sigma-Aldrich (Steinheim, Germany) 13C2 - Ethinyl estradiol Cambridge Isotope Laboratories (Andover, MA, 
USA) 
Fexofenadine Sigma-Aldrich (Steinheim, Germany) 2H6 - Amitriptyline Cambridge Isotope Laboratories (Andover, MA, 
USA) 
Finasteride Sigma-Aldrich (Steinheim, Germany) 2H5 - Oxazepam Sigma-Aldrich (Steinheim, Germany) 
Fluconazole Sigma-Aldrich (Steinheim, Germany) 13C3 - Trimethoprim Cambridge Isotope Laboratories (Andover, MA, 
USA) 
Fluoxetine Sigma-Aldrich (Steinheim, Germany) 2H5 - Fluoxetine Cambridge Isotope Laboratories (Andover, MA, 
USA) 
Flutamide Sigma-Aldrich (Steinheim, Germany) 2H6 - Amitriptyline Cambridge Isotope Laboratories (Andover, MA, 
USA) 
Hydroxyzine Sigma-Aldrich (Steinheim, Germany) 2H6 - Amitriptyline Cambridge Isotope Laboratories (Andover, MA, 
USA) 
Irbesartan CHEMOS GmbH (Regenstauf, Germany) 2H6 - Amitriptyline Cambridge Isotope Laboratories (Andover, MA, 
USA) 
Maprotiline Sigma-Aldrich (Steinheim, Germany) 2H6 - Amitriptyline Cambridge Isotope Laboratories (Andover, MA, 
USA) 
Memantine Sigma-Aldrich (Steinheim, Germany) 13C2H3 - Tramadol Cambridge Isotope Laboratories (Andover, MA, 
USA) 
Metoprolol Sigma-Aldrich (Steinheim, Germany) 13C2H3 - Tramadol Cambridge Isotope Laboratories (Andover, MA, 
USA) 
Mianserin Sigma-Aldrich (Steinheim, Germany) 13C2H3 - Tramadol Cambridge Isotope Laboratories (Andover, MA, 
USA) 
Mirtazapine Sigma-Aldrich (Steinheim, Germany) 13C2H3 - Tramadol Cambridge Isotope Laboratories (Andover, MA, 
USA) 
Naloxone Sigma-Aldrich (Steinheim, Germany) 13C2H3 - Tramadol Cambridge Isotope Laboratories (Andover, MA, 
USA) 
Orphenadrine LGC Standards (Middlesex, UK) 2H6 - Amitriptyline Cambridge Isotope Laboratories (Andover, MA, 
USA) 
Paroxetine Sigma-Aldrich (Steinheim, Germany) 2H6 - Amitriptyline Cambridge Isotope Laboratories (Andover, MA, 
USA) 
Pizotifen LGC Standards (Middlesex, UK) 2H6 - Amitriptyline Cambridge Isotope Laboratories (Andover, MA, 
USA) 
Promethazine Sigma-Aldrich (Steinheim, Germany) 2H6 - Amitriptyline Cambridge Isotope Laboratories (Andover, MA, 
USA) 
Repaglinide Sigma-Aldrich (Steinheim, Germany) 2H6 - Amitriptyline Cambridge Isotope Laboratories (Andover, MA, 
USA) 
Risperidone LGC Standards (Middlesex, UK) 2H4 - Risperidone Sigma-Aldrich (Steinheim, Germany) 
Sotalol Sigma-Aldrich (Steinheim, Germany) 13C2H3 - Tramadol Cambridge Isotope Laboratories (Andover, MA, 
USA) 
Sulfamethoxazole Sigma-Aldrich (Steinheim, Germany) 13C6 - Sulfamethoxazole Cambridge Isotope Laboratories (Andover, MA, 
USA) 
Telmisartan Sigma-Aldrich (Steinheim, Germany) 2H6 - Amitriptyline Cambridge Isotope Laboratories (Andover, MA, 
USA) 
Tramadol Sigma-Aldrich (Steinheim, Germany) 13C2H3 - Tramadol Cambridge Isotope Laboratories (Andover, MA, 
USA) 
Trihexyphenidyl Sigma-Aldrich (Steinheim, Germany) 2H6 - Amitriptyline Cambridge Isotope Laboratories (Andover, MA, 
USA) 
Trimethoprim Sigma-Aldrich (Steinheim, Germany) 13C3 - Trimethoprim Cambridge Isotope Laboratories (Andover, MA, 
USA) 
Venlafaxine Sigma-Aldrich (Steinheim, Germany) 13C2H3 - Tramadol Cambridge Isotope Laboratories (Andover, MA, 
USA) 
Zolpidem LGC Standards (Middlesex, UK) 13C2H3 - Tramadol Cambridge Isotope Laboratories (Andover, MA, 
USA) 
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Table S2 
Ionization mode, recoveries and relative standard deviation (RSD) of the APIs  
 
API Ionization mode Recovery (average of triplicate) RSD  
% % 
Alfuzosin HESI 111 6.2 
Alprazolam HESI 67.8 2.8 
Amitryptiline HESI 83.3 7.5 
Atracurium HESI 85.8 7.2 
Beclomethasone HESI 25.2 12.9 
Bezafibrate HESI 126 1.1 
Biperiden HESI 106 8.4 
Bisoprolol HESI 83.1 5.1 
Budesonide HESI 111 9.5 
Buprenorphine HESI 88.6 5.3 
Bupropion HESI 96.3 4.7 
Carbamazepine HESI 101 15.1 
Cilazapril HESI 143 5.9 
Ciprofloxacin HESI 86.3 4.1 
Citalopram HESI 83.6 8.5 
Clindamycine HESI 76.7 9.4 
Clonazepam HESI 67.6 5.8 
Codeine HESI 86.7 24.0 
Cyproheptadine HESI 80.0 2.4 
Desloratidine HESI 57.1 4.0 
Diclofenac HESI 42.1 4.4 
Dicycloverin HESI 84.1 7.7 
Diltiazem HESI 107 3.8 
Diphenhydramine HESI 99.0 15.1 
Dipyridamole HESI 72.0 7.6 
Eprosartan HESI 62.3 4.3 
Estriol APCI/APPI 129 24.7 
Estrone APCI/APPI 134 19.9 
Ethinyl estradiol APCI/APPI 85.7 4.1 
Fexofenadine HESI 81.1 7.1 
Finasteride HESI 80.0 5.1 
Fluconazole HESI 89.8 12.9 
Fluoxetine HESI 97.0 11.4 
Flutamide HESI 91.8 3.9 
Hydroxyzine HESI 94.5 14.2 
Irbesartan HESI 109 2.6 
Maprotiline HESI 84.1 7.4 
Memantine HESI 85.7 7.7 
Metoprolol HESI 82.9 1.3 
Mianserin HESI 81.0 12.5 
Mirtazapine HESI 90.3 17.3 
Naloxone HESI 75.8 30.2 
Orphenadrine HESI 94.7 11.2 
Paroxetine HESI 62.7 5.5 
Pizotifen HESI 90.8 5.3 
Promethazine HESI 108 6.7 
Repaglinide HESI 93.4 8.6 
Risperidone HESI 101 2.4 
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Sotalol HESI 125 14.7 
Sulfamethoxazole HESI 97.3 4.3 
Telmisartan HESI 106 15.2 
Tramadol HESI 129 6.3 
Trihexyphenidyl HESI 124 12.2 
Trimethoprim HESI 109 10.7 
Venlafaxine HESI 96.2 7.8 
Zolpidem HESI 94.3 4,4 
Median 91 7.3 
Min 25 1.1 
Max 143 30 
 
Note:  
Recovery experiment at 1000 ng/L (n=3).  3 APIs has recovery of < 60%; 1 API has recovery 
of > 130% 
 
 
 
 
 
 
 
 
 
 
 
 
